Activating mutations or copy number gains in JAK/STAT pathway components have become an interesting field for research in CTCL and promising targets for therapy [3,5,10,11]. This evidence concerns the gene SOAT1 and primary cutaneous T-cell non-Hodgkin lymphoma.